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Surveillance is a key component of controlling antimicrobial resistance.  In the 
United States this function is carried out by the National Antimicrobial Monitoring 
System.  This effort combines the United States Department of Agriculture Food 
Safety Inspection Service collecting samples from slaughter facilities, the Food and 
Drug Administration collection samples from retail and the Center for Disease Control 
collecting samples from human medicine. In order to better understand single and 
multi-drug resistance as well as how their monitoring could be improved a 
comprehensive analysis of this surveillance data was undertaken.   
After an introductory chapter, the second chapter presents an analysis of single 
drug resistance measured both in terms of the amount of antibiotic required to prevent 
bacterial growth, minimum inhibitory concentration, and the proportion of isolates 
exceeding a given resistance cutoff.  The effects of measuring resistance in these two 
different ways are compared along with the consequences of resistance cutoff choices.  
An analysis of variability is then carried out and used in an assessment of power and 
sample sizes.  The examination of trends in single drug resistance reveals that these 
trends depend very much on the host, bacteria, and antimicrobial context regardless of 
whether one considers minimum inhibitory concentration or resistance proportion and 
that the resistance cutoff chosen has a dramatic impact on the nature of the trend 
 observed.  Measurements of single drug resistance are overdispersed which means 
large sample sizes are required to detect changes in resistance.   
The third chapter focuses on identifying multi-drug resistance associations by 
constructing contingency tables of resistance counts and modeling then with log-linear 
models.   This approach uncovers associations that are in some cases so extreme they 
cannot be tested for using asymptotic or exact conditional methods and instead require 
a Bayesian approach.  Interrogation into the nature of these interactions reveals a 
spectrum of interactions including a hierarchy among the β-lactams.   
The fourth chapter explores the variability of interactions discovered in chapter 
three.   As was the case with single drug resistance, multi-drug resistance also displays 
more variability than expected.  This increased variability or overdispersion is likely 
due to unaccounted factors like antimicrobial use, husbandry practices and food 
handling hygiene procedures.  
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CHAPTER 1 
INTRODUCTION 
Overview 
A key component of controlling antimicrobial resistance is surveillance.  
National surveillance systems are essential because they keep track of the resistance 
levels being experienced at various places in a country across time.  They are not an 
experiment so they cannot conclusively elucidate underlying mechanisms, but they 
can shed light on potential mechanisms.  More importantly by recording resistance 
levels they can alert regulators to problems and provide a historical record of how the 
problem arose.  In monitoring antimicrobial resistance, there are two levels.  Single 
drug resistance monitoring is concerned with of the resistance of microbes to 
individual antimicrobials and how this resistance changes in different situations like 
geographic location, host environment, or time.  Multi-drug resistance monitoring is 
concerned with simultaneous resistance to multiple drugs, which drug resistances are 
coupled together, and how these associations change with changing environments.  In 
the United States, antimicrobial resistance surveillance is carried out by the National 
Antimicrobial Monitoring System (NARMS).  What follows is a detail analysis of 
single drug, and multi drug resistance in the United States as captured by NARMS. 
The National Antimicrobial Monitoring System (NARMS) 
  NARMS consists of 3 components.  The United States Department of 
Agriculture Food Safety and Inspection Service (USDA-FSIS) collects isolates from 
animal slaughter facilities, the Food and Drug Administration (FDA) collects isolates 
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from retailers, and the Center for Disease Control and Prevention (CDC) collects 
isolates from humans (NARMS, 2016a).  The program focuses on Salmonella, 
Campylobacter, Escherichia, and Enterococcus.  The CDC also monitors Shigella, 
and Vibrio. 
 The slaughter samples collected by FSIS are collected as part of its Pathogen 
Reduction/Hazard Analysis and Critical Control Point (PR/HACCP) food safety 
monitoring of slaughter facilities (NARMS, 2016a).  Since food safety, not 
antimicrobial resistance surveillance is the primary purpose of PR/HACCP the 
slaughter component of the surveillance system does not have a single design, but it’s 
design changes as regulators adapt PR/HACCP procedures to improve the efficacy and 
efficiency of food safety monitoring.  This component of NARMS began in 1997.  At 
this time FSIS selected slaughterhouses for sampling based on a two-tiered system.  In 
the first tier, facilities were sampled at random with the goal of visiting each facility 
once a year.  In the second tier, facilities with compliance violations were subject to 
additional sampling.  Most samples were collected through the first tier, but no record 
is available of whether an isolate was sampled as part of tier one or tier two.  No 
information is available on the location of the facility, either.  At the beginning only 
Salmonella was sampled.  For chickens, samples were isolated from carcass rinses, 
and ground products.  For turkey, samples were isolated from carcass swabs and 
ground products.  Swine samples were isolated from carcass swabs and cattle samples 
were isolated from ground products.  Campylobacter sampling began a year later in 
1998 from chicken carcass rinses submitted to the eastern lab.  In June 2006 FSIS 
changed the way it selected slaughterhouses to focus on those with higher amounts of 
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Salmonella and Salmonella serotypes of public health concern.  In 2011 FSIS stopped 
sampling cows and bulls due to low bacterial yield.  They also began testing for 
Campylobacter from young chicken and turkey carcasses at all 3 laboratories.  A year 
later in 2012 sampling of market hogs, steers and heifers was discontinued again 
because they contained so few bacteria. In 2013 FSIS began continuous sampling of 
Salmonella from comminuted chicken and turkey.  They also began a cecal sampling 
program.  In this program facilities are randomly selected based on facility size, 
animal class, and slaughter volume.  For chickens and turkeys, samples are taken from 
groups of 5 young birds.  For swine, samples are taken from individual market swine 
and sows.  For cattle, samples are taken from individual dairy cows, beef cows, steers, 
and heifers.  In 2014 FSIS stopped testing ground beef unless a facility had failed its 
last inspection but began testing all raw beef samples collected for shiga-toxing 
producing Escherichia coli providing a small non-risk based sample set. 
 The retail sample collection program run by FDA is essentially its own study 
and thus the design has been fairly constant over time (NARMS, 2016a).  Retail meet 
sample collection began in 2002 with sites participating in the Foodborne Diseases 
Active Surveillance Network.  These include Connecticut, Georgia, Maryland, 
Minnesota, Oregon and Tennessee.  New York, California, Colorado and New Mexico 
joined the program over the course of the next 2 years. Pennsylvania joined in 2008, 
Missouri, Louisiana, and Washington joined in 2012 and Iowa, Kansas, South Dakota 
and Texas joined in 2016.  All sites select retailers to visit by identifying all zip codes 
in a 50-mile radius, identifying all retailers in those zip codes using the Chain Store 
Guide, dividing the zip codes into quadrants, and randomly selecting a subset of the 
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stores in each quadrant.  Quadrants are randomly ordered across the twelve months.  
Each month forty meat samples are chosen.  Ten of the samples are chicken breasts 
with bone in and skin on.  Since 2011 wings, legs or thighs in that order of preference 
will be taken if no breasts are available.   Ten of the samples are ground turkey.  Ten 
of the samples are 80% lean ground beef. The final ten samples are pork chops.  
Salmonella are isolated from all sites and all meat types.  All sites isolate 
Campylobacter form chicken and turkeys expect for Pennsylvania during its first year 
in the program.  Beef and Swine stopped being sampled for Campylobacter in 2008 
due to low incidence.  George, Oregon, Maryland and Tennessee also sample for 
Escherichia and Enterococcus. 
 The human samples program run by CDC is also essentially its own study and 
has a fairly constant design (NARMS, 2016a).  The program began in 1996 with 
sampling of non-Typhi Salmonella and E. coli 0157 from the food net sites 
Connecticut, Georgia, Maryland, Minnesota, Oregon, Tennessee, New York, 
California, Colorado, New Mexico, Pennsylvania, Missouri, Louisiana, and 
Washington.  In 1997 Campylobacter testing began and expanded to California, 
Connecticut, Colorado, Georgia, Maryland, Minnesota, New Mexico, New York, 
Oregon, and Tennessee by 2003.  In 1999 Salmonella serotype Typhi and Shigella 
testing began. In 2003 Salmonella, Shigella and E. coli O157 testing was expanded to 
all states.  In 2009 sampling of Vibrio species other than V. cholera was added. 
Antimicrobial Resistance Testing 
 NARMS determines antimicrobial resistance using the broth microdilution 
method (NARMS, 2015; NARMS 2016b).  Specifically, colonies are isolated onto 
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microbe specific media.  A colony is picked from those isolated from each source and 
grown in broth spiked with serial dilutions of the antibiotic being tested for.  Growth is 
determined spectrophotometrically by comparing the amount of light reflected by an 
inoculated sample to that reflected by a control sample with an increase in light 
reflection indicating bacterial growth.  The lowest dilution that prohibits grown is 
termed the minimum inhibitory concentration (MIC).  MIC values can be converted to 
a susceptible/resistance value using a relevant resistance cutoff (FDA, 2014). 
Previous Work 
 The results of the NARMS program is summarized each year in a number of 
government reports, most notably the annual NARMS integrated report (FDA, 2014).  
This report focus on the percentage of isolates exceeding the chosen resistance cutoffs. 
For single drug resistance, it covers a number of specific microbe/antibiotic case 
studies chosen either because of the importance of the microbe as a pathogen and the 
importance of the antibiotic in treating infections of the given pathogen or because of 
the usefulness of the particular microbe/antibiotic combination as a general indicator 
of trends in antimicrobial resistance.  At the level of multidrug resistance, the 
integrated report discusses the number of isolates that are resistance to 3 or more drugs 
making no distinction between the three drugs to which the microbe is specifically 
resistant.  The report also focuses on the extended spectrum beta-lactamase (ESBL) 
resistance pattern and the ampicillin, chloramphenicol, streptomycin, sulfonamides, 
and tetracycline (ACSSuT) resistance pattern.  ESBL isolates are determined by taking 
isolates resistant to beta-lactam antibiotics like ceftriaxone and cefoxitin, sequencing 
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their genomes, and determining if they possess known ESBL genes.  ACSSuT 
resistance is determined based on the phenotypic data. 
 In hopes of more fully characterizing multidrug resistance several authors have 
developed methods that try to move beyond the known multidrug patterns and learn 
new association patterns directly from surveillance data.  One of these relies on an ad 
hoc strategy for assembling additive Bayesian models (Lugwig, 2013).  A second 
makes use of the graphical lasso (Love, 2016). 
Current Work 
 The work that follows builds on this research in order to provide a more 
comprehensive understanding of the NARMS dataset on both the single drug and the 
multidrug resistance fronts. 
 The next chapter builds out the single drug front by analyzing all microbe, 
antibiotic, and host combinations.  For each combination resistance at slaughter and 
retail stages was compared in order to understand how resistance changes as meat 
products move through the supply chain.  A comparison of trends in resistance as 
defined by the NARMS susceptibility/resistance cutoffs and resistance as defined by 
continuous MIC values was carried out as well as an analysis of how choice of 
resistance cutoff effects these trends.  The amount and causes of variability in the 
dataset was formally analyzed.  Finally, this analysis of variability to used to 
understand the power to detect changes in antibiotic resistance over time provided by 
the NARMS dataset. 
 The following chapter builds out the multidrug front by applying log-linear 
models of contingency tables to understand the structure of multidrug associations.  In 
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particular, by using a log-linear model strategy this chapter moves beyond the 2-way 
interactions detected in the additive Bayesian models and the graphical lasso to detect 
higher order interactions.  Since many of these interactions turn out to be difficult to 
detect with standard asymptotic methods and exact conditional methods a Bayesian 
test is developed.  Finally, the potential biological significance of the detected 
interactions is examined. 
 The final chapter examines how the variability observed in the second chapter 
effects the interactions inferred in the third.  First, the amount of variation expected for 
a multinomial random variable is compared to the amount observed in the multidrug 
contingency tables.  Since multidimensional variability is difficult to make sense of, 
an analysis of the variability in the interaction terms is carried out.  A power analysis 
is carried out using the assumption of asymptotic normality for the interaction 
parameters and compared to a more exact power analysis using a Dirichlet 
multinomial simulation. 
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CHAPTER 2 
 
MONITORING ANTIMICROBIAL RESISTANCE IN THE FOOD SUPPLY 
CHAIN AND ITS IMPLICATIONS FOR FDA POLICY INITITIVES 
Introduction 
Antimicrobial resistance (AMR) is one of the most serious health threats to 
both animals and humans. The mitigation of AMR in animal agriculture is therefore 
critical for both the agri-food industry and for public health (Oliver, 2011; Marshall 
2011).  Globally and nationally, there is much attention on developing approaches to 
mitigate AMR (WHO 2011; The White House 2015; FDA 2012; FDA 2013a). 
Overuse of antimicrobials contributes to the emergence and proliferation of resistant 
bacterial strains. Historically, antimicrobials have been administered to livestock and 
poultry to address both animal health as well as production purposes.  In order to slow 
down the development and proliferation of AMR in food animal agriculture, the Food 
and Drug Administration (FDA) has initiated a risk mitigation strategy to limit use of 
medically important antimicrobials to therapeutic uses under veterinary oversight by 
working with drug companies to change product labels (FDA 2012; FDA 2013a).  
A key piece of evidence in evaluating the efficacy of this policy is detecting the 
change in AMR before and after the policy has been implemented. To do so, it is 
necessary to understand the baseline variation of AMR over time and at different 
stages of the food supply chain.  The most comprehensive information on AMR in 
United States agriculture is the newly public data from the National Antimicrobial 
Resistance Monitoring System (NARMS).  NARMS longitudinally monitors 
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resistance of non-typhoidal Salmonella, Campylobacter spp., Escherichia coli, and 
Enterococcus spp. to a variety of antibiotics (FDA, 2015a).  Resistance of each isolate 
is reported as a minimum inhibitory concentration (MIC) which can then be 
transformed into a susceptible/resistance value based on whether this MIC exceeds a 
given resistance threshold.  Where defined, NARMS uses the clinical breakpoints 
published by the Clinical and Laboratory Standards Institute (CLSI) to interpret MIC 
values as susceptible or resistant, and uses epidemiological cut-offs where clinical 
breakpoints are not defined (FDA, 2015b).  The clinical breakpoints defined by CLSI 
are determined by the probability of therapeutic failure in humans and are intended to 
guide clinical decision making (Martínez, 2014).  Epidemiological cutoffs represent 
the level of resistance which demarcates the boundary between the wild type 
population and resistant mutants.  They are determined as the value that separates the 
main part of the MIC distribution from the upper tail (Martínez, 2014).  
The historical trends of AMR have been preliminarily explored in the annually 
published NARMS reports. These reports focused on resistance proportions and 
modeled slaughter and retail separately.  Dichotomizing MIC values however risks a 
loss of information (Naggara, 2011; Fedorov 2009).  Dichotomization of MIC results 
also cannot detect shifts from low to high resistance levels, which provide an early 
warning for increasing resistance in a population.   Clinical breakpoints may also shift 
over time to reflect changes in AMR interpretation, reporting, and methods, resulting 
in changes in reported resistance proportions not related to changes in population 
(Hombach, 2013; Hamada, 2015).  Pulsed-field gel electrophoresis (PFGE) profiles of 
Campylobacter and Salmonella from broiler flocks found identical clones from 
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primary production through slaughter to retail products (Lienau, 2007; Nógrády, 
2008), indicating that there may be a connection between resistance levels at various 
stages of the food supply chain. 
The objectives of this study were to evaluate the baseline trend and variations 
in the NARMS data and provide useful information to improve data collection, 
analysis and synthesis in the national AMR monitoring system. To achieve these, we 
extended the annual NARMS reports by examining both percent resistance and mean 
MIC values. Moreover, we considered each of these values simultaneously at the 
slaughter and retail stage.  We examined the structure of the variation in resistance 
within\between years, and across geographic regions.  Using this baseline, we 
estimated how much data must be collected to be able to determine if the change in 
FDA policy did indeed have an effect. Finally, using this information we examined the 
impact of a previous change in FDA antimicrobial policy, removing approval of 
enrofloxacin for use in poultry water in 2005. 
Materials and Methods  
The dataset 
The NARMS data were obtained from the FDA website. The data files for 
Retail Meats, HACCP 1997-2005, HACCP 2006-2013 and Cecal were combined and 
stored in an SQLite database. MIC values were log2 transformed, which reduced 
skewness (Wagner, 2003).  The MICs of isolates susceptible to the lowest antibiotic 
concentration tested were taken to be this lowest concentration and the log2 
transformed MICs of isolates resistant to the highest concentration tested were 
incremented by 1.  
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 Although we examined many different combinations of microbes, hosts and 
antibiotics, we focus here on chicken as the host and examined resistance of 
Campylobacter jejuni to tetracycline, Campylobacter coli to erythromycin, Salmonella 
enterica serovar Typhimurium to ampicillin, and Escherichia coli to streptomycin. In 
accordance with NARMS guidelines resistance for all Campylobacter and E. coli-
streptomycin was determined using epidemiological cutoffs and resistance for S. 
Typhimurium-Ampicillin was determined based on the CLSI breakpoint (USDA 
2014).   Chicken data had the most consistent data across all time points and stages.  
Analyzed drugs were chosen not only for their significance in human medicine, but 
also for their importance in veterinary medicine and extent of use in food production 
(FDA, 2003). Bacteria were selected for their significance as pathogens, number of 
observations, and MIC distribution patterns.  The time frame of 2004 to 2012 was 
chosen because both slaughter and retail data for chicken were available during this 
time period (retail data were first available in 2004 and 2012 was the last year the 
HACCP slaughter data were available), which made the stage effect analysis possible. 
Sample per year and stage ranged from 21 to 2232. 
MIC distributions over time and across stages    
In order to obtain a baseline understanding of AMR changes over time and 
across different stages of the food supply chain (i.e., slaughter and retail), we began by 
first exploring the resistance data for each microbe/host/antibiotic combination.  Line 
graphs were used to visualize resistance data and boxplots were used to visualize the 
distribution of the MICs.  
Generalized linear modeling of resistance  
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To quantitatively assess trends in AMR, we constructed models of resistance 
both as a binary variable using logistic regression and as a continuous variable using 
linear regression, using log2 (MIC).  To quantitatively assess the sources of variation 
we constructed a linear mixed effects model.  All models were implemented using the 
Python Statsmodels package (Seabold, 2010).  The significance of all coefficients was 
assessed using a likelihood ratio test. 
Modeling resistance prevalence – logistic regression 
Logistic regression was carried out by modeling the log odds of resistance 
versus non-resistance as a function of stage and year. We chose 2004 retail data as the 
baseline level. The model is shown in equation 1  
ln  	 =  + +ℎ +          (1) 
where α and β are coefficients, i indexes over the years, j indexes over slaughter and 
retail stages, and Slaughter is an indicator variable designating whether the sample 
came from slaughter or retail.  The e term is the error. 
To determine the robustness of this analysis to the choice of resistance 
threshold C. coli-erythromycin was taken as an example and the regression was 
carried out using each MIC as a cutoff. The stability of the model was evaluated based 
on the similarity of the resulting coefficients.  
Modeling MIC distribution – linear regression 
As a means of both sidestepping the choice of a breakpoint, and adding an 
additional viewpoint on AMR, MIC was treated as a continuous variable and the mean 
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log2 MIC was modeled as a linear function of stage and year. The linear model is 
shown in equation 2. 
!"#$% = +&ℎ +  +          (2) 
Modeling sources of variation – linear mixed effects model 
To study the sources of variation in resistance, log2 MIC at each stage was 
modeled separately as a function of a fixed intercept for state and a random intercept 
for year according to equation 3. 
!"#$%' = ( + ) + ' + '        (3) 
Here i indexes over years and k indexes over the states. 
Power analysis  
To formally evaluate the effectiveness of the FDA policy change in a manner 
consistent with the exploratory and regression analyses, we propose a model with a 
constant base level of resistance around which the yearly levels vary, a period of 
change, and then a new resistance level is established (Figure 1).  Under this model a 
hypothesis test of mean resistance level before and after the policy change can assess 
the change in resistance.  It is assumed that there is a different amount of variation 
within years and between years so the test is carried out on average yearly resistance. 
This test can be done with either percent resistance or MIC values (SAS, 2004).  A 
power analysis was performed to benchmark the efficacy of this test.  Calculating 
power requires knowledge of the standard deviation, sample size, and magnitude of 
the effect to be detected.  For the t-test of mean log2 MIC sensible standard deviations 
were selected by calculating the empirical distribution for the standard deviation of the  
 25 
 
Figure 1: Model of Antimicrobial Resistance  
The model of antimicrobial resistance used in evaluating policy changes.  It is 
assumed there is a constant base level of resistance around which the yearly levels 
vary, a period of change, and then a new resistance level is established. 
 
 
mean log2 MIC per year.  The number of isolates per year was assumed to be 200, a 
number generally exceeded in historical data.  The current 9 years of data were used as 
the pre-policy change sample size.  Post-policy change sample sizes were assumed to 
be between 1 and 10 years.  The desired detectable effect was taken to be between 0 
and 1 log2 MIC.  Power curves were then plotted according to equation 4. 
power = /0 1 22_4_567 + /0 8 22_4_7        (4) 
where  = √:;" <=>????	=>????& A  with n-2 degrees of freedom and non-centrality parameter δ 
where B = √:;;" <CDEEF A.  tcritical_val_low is the	G" quantile of the central t distribution 
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with n-2 degrees of freedom, tcritical_val_up is the	1 − G" quantile of the central t 
distribution with n-2 degrees of freedom, n is the total number of observations, and the 
w’s the fraction of observations in each sample. 
Resistant/Susceptible counts are binomial quantities and so their standard 
deviations are functions of the proportions.  However, because the data come from a 
mix of conditions like geographical location, season, and production quality these 
proportions are over-dispersed with respect to binomial variation, and the standard 
deviation will also be a function of this over-dispersion parameter.  Reasonable 
proportions and over-dispersion parameters were obtained by plotting the empirical 
distribution of each quantity.  Isolates per year was set to 200, pre-policy change 
sample size was 9 years, post-change sample size was between 1 and 10 years, and 
effect sizes were chosen so as to be detectable with such sample sizes.  The power 
curves were then plotted according to equation 5. 
power = 	Φ <K56 − >L& A + 1 − Φ<K − >L& A        (5) 
where r = M NO< LPL LP>AQLNLRQLOPL SQ>NLRQ>OP> ,  T = UV
LNLOW'L + >N>OW'> ,  X = 'L' X + '>' X", Φ is the 
normal PDF, c a critical value, k the number of years in a sample and V the over-
dispersion.  
The role of isolate count was determined by calculating power as in equation 4, 
but replacing the single standard deviation parameter s with the combination of 
between year and within year standard deviations in equation 6. 
s = 	UTZ6W" + &[\]^>W         (6) 
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where n is the number of isolates per year.  The resulting power was plotted for n 
between 1 and 2000 assuming TZ6W is .6, T6W is 3, the pre-policy change 
sample size was 9 years, post-change sample size was 5, and the effect size was a 1 
fold change in MIC. 
In assessing power .8 was chosen as the desirable threshold.   
Assessing the effect of the change in enrofloxacin policy  
In 2005 the FDA withdrew of approval of enrofloxacin in poultry water.   Due 
to this policy change having much the same form as the current policy change it serves 
as a useful case study.  Since enrofloxacin is metabolized to ciprofloxacin the analysis 
focused on the latter antibiotic.  We evaluated its resistance using the exploratory 
analysis, generalized linear models and t-test as in the baseline study.  Since the policy 
change occurred in 2005 we extended to time period under consideration back to 
2002. 
Results 
Analysis of MIC distributions over time and across stages  
Preliminary analysis of the raw data revealed that the trend in AMR was 
largely dependent on the bacteria-drug combination.  In most cases like C. jejuni-
ciprofloxacin, C. jejuni-tetracycline, C. coli-erythromycin, S. typhimurium-ampicillin, 
average log2 MIC increased slightly over time (Figures 2-4). In other cases like E. 
coli-streptomycin there was a marked decrease in resistance during the study period 
(Figure 5).  The relationship between slaughter and retail was also case dependent  
with slaughter sometime higher than retail and retail sometimes higher than slaughter.  
The distribution of MICs was generally highly skewed, in many cases the median, first 
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quartile, and even the minimum all coincided.   The percent resistance followed the 
same trend as the log2 MIC, but with much higher variability.  
Logistic modeling   
The logistic model (Table 1) confirmed the results of the exploratory analysis.  
Both the coefficients themselves and the significant coefficients were dependent on 
the specific drug-bacteria combination.  Although the intercept and at least one of the 
year coefficients was significant in all cases, which particular year coefficient was 
significant varied widely.  For E.coli-Streptomycin all year coefficients were 
significant.  In C. coli-Erythromycin only the coefficient for 2011 was significant.  
The coefficient for slaughter was significant for E. coli-Streptomycin and S. 
Typhimurium-Ampicillin.  It was not significant for C. coli-Erythromycin or C. jejuni-
Tetracycline, not because there was no difference between slaughter and retail, but 
because slaughter was sometimes higher than retail and sometimes lower.  
The distribution of MIC (Figure 6) for C. coli-erythromycin showed that at 
both slaughter and retail there was one narrow peak above the log2 MIC cutoff of 5 
and a broad peak between -1 and 2. The broad peak between -1 and 2 is likely to 
represent the MIC distribution for the wild-type isolates, while the isolates with log2 
MIC above 5 are likely to represent the non-wild type isolates. The sensitivity analysis 
(Table2) showed that the model was highly sensitive to the choice of cutoff. For all the 
years, the coefficients in the logistic models vary to a large degree with the choice of 
cutoff. Many of the coefficients are negative in some models and positive in others.  
The identity of the significant coefficients also changes between models.  This 
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suggests that while estimating the proportion of bacteria with resistance above a 
threshold is important it does not tell the whole story.  
 
 
 
Figure 2: Exploratory analysis of Campylobacter jejuni resistance to tetracycline.  
A) Boxplots of log2 minimum inhibitory concentration (MIC).  The lower whisker is 
the minimum observed MIC in a given year, the lower edge of the box the first 
quartile, the line the median, the square the mean, the top of the box the third quartile, 
and the upper whisker the maximum. The dashed line indicates the breakpoint 
between resistant and susceptible isolates.  B) Line graph of percent isolates with MIC 
values above the resistance breakpoint. Sizes of points are proportional to the number 
of observations in the given year and stage. Sample sizes ranged from 78 to 1,348. 
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A)  
Figure 3: Exploratory analysis of Campylobacter coli resistance to erythromycin.    
A) Boxplots of log2 minimum inhibitory concentration (MIC).  The dashed line 
indicates the breakpoint between resistant and susceptible isolates.  B) Line graph of 
percent isolates with MIC values above the resistance breakpoint. Sizes of points are 
proportional to the number of observations in the given year and stage. Samples sizes 
ranged from 76 to 693. 
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Figure 4: Exploratory analysis of Salmonella Typhimurium resistance to Ampicillin.    
A) Boxplots of log2 minimum inhibitory concentration (MIC).  The dashed line 
indicates the breakpoint between resistant and susceptible isolates.  B) Line graph of 
percent isolates with MIC values above the resistance breakpoint. Sizes of points are 
proportional to the number of observations in the given year and stage. Samples sizes 
ranged from 21 to 104. 
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Figure 5: Exploratory analysis of Escherichia coli resistance to streptomycin.    
A) Boxplots of log2 minimum inhibitory concentration (MIC).  The dashed line 
indicates the breakpoint between resistant and susceptible isolates.  B) Line graph of 
percent isolates with MIC values above the resistance breakpoint. Sizes of points are 
proportional to the number of observations in the given year and stage. Samples sizes 
ranged from 299 to 2232. 
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Table 1: Values of coefficients for the logistic regression of resistance on year and 
stage.   
 
C. coli -
Erythromycin 
C. jejuni -
Tetracycline 
E. Coli -
Streptomycin 
S. Typhimurium -
Ampicillin α -2.29* -0.19* 0.31* 0.81* 
β2005 -0.04 -0.03 -0.25* -0.67* 
β2006 -0.28 0.19 -0.54* -0.06 
β2007 0.00 0.23* -0.65* -0.37 
β2008 0.10 0.21 -0.43* -0.49* 
β2009 -0.64 0.05 -0.63* -0.13 
β2010 -0.88 -0.21 -0.64* -0.12 
β2011 -0.87* 0.05 -0.55* -0.51* 
β2012 0.00 0.16* -0.82* -0.59* 
βSlaughter 0.00 0.03 0.26* -1.13* 
* significant at α=.05 
 
Linear modeling  
To obtain a more complete picture a linear model of mean log2 MIC was also 
fit (Table 3).  This model confirmed that in general both the year and slaughter 
coefficients were significant but that the identity of the significant coefficients as well 
as their values depended on the bacteria-drug combination. 
Mixed effects model 
The standard deviation of the year random effect ranges from 0 to 2 and is generally 
below 1 (Figure 7). Without the state fixed effect the residual standard deviation 
ranges from 0 to 4.25 and except for cases of very low total standard deviation is 
almost always greater than the amount of variation explained by year.  The addition of  
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Figure 6: Distribution of log2 MIC for Campylobacter coli resistance to erythromycin.  
A) Distribution at retail. B) Distribution at slaughter. Counts are summed over the full 
range of years, 2004 to 2012. 
 
 
 
Figure 7: Variation Composition. 
Scatterplot of between year standard deviation vs. residual standard deviation across 
all bacteria, drug, stage combinations. 
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Table 2: Sensitivity of logistic regression of resistance to choice of breakpoint.  Data 
are for Campylobacter coli resistance to erythromycin. Column labels specify the log2 
MIC breakpoint used to distinguish resistant and susceptible.  The final column, 5, 
represents the clinically relevant breakpoint.  
 Breakpoint log2 MIC 
 -1 0 1 5 
α 0.93* 0.06 -1.46* -2.29* 
β2005 0.20 0.51* 0.19 -0.04 
β2006 0.29 0.78* 0.53* -0.28 
β2007 0.40* 0.71* 0.23 0.00 
β2008 0.72* 0.57* 0.40 0.10 
β2009 0.69* 0.23 -0.10 -0.64 
β2010 -0.01 -0.22 -0.71* -0.88 
β2011 0.17 -0.16 -0.82* -0.87* 
β2012 0.57* 0.41* 0.21 0.00 
βSlaughter -0.30* -0.54* -0.61* 0.00 
* significant at α=.05 
 
 
Table 3: Values of coefficients for the linear regression of log2 MIC on year and stage. 
 
C. coli -  
Erythromycin 
C. jejuni - 
Tetracycline 
E. Coli - 
Streptomycin 
S. Typhimurium - 
Ampicillin α -0.11 1.89* 5.58* 3.52* 
β2005 0.10 -0.69* -0.06* -0.71* 
β2006 0.23 -0.07 -0.13* -0.11 
β2007 0.27 0.02 -0.16* -0.47 
β2008 0.35 0.08 -0.10* -0.62* 
β2009 -0.04 -0.26 -0.15* -0.18 
β2010 -0.44* -0.85* -0.16* -0.19 
β2011 -0.36* -0.30 -0.13* -0.63* 
β2012 0.23 -0.17 -0.20* -0.69* 
βSlaughter -0.30* 0.05 0.06* -1.33* 
* significant at α=.05 
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the state fixed effect does little to change this, decreasing the residual standard 
deviation by less than .25. 
Power analysis  
As the first step of the power analysis we determined that across all bacteria, 
drug, stage combinations the standard deviation of the log2 MIC values decreased 
sharply from 0 with most values below .6 and almost all below 1 (Figure 8).  As a 
result power curves were plotted for standard deviation of .6 and 1.  These curves 
indicate that at a standard deviation of .6 it would be possible to detect a 1 log2 MIC 
change in 5 years, and at a standard deviation of 1 a 1.5 unit log2 MIC change could be 
detected in 7 years.   
In analyzing the power of the proportion test it was determined that the vast 
majority of average resistance proportions across all bacteria, drug, stage 
combinations were below .25 with most were below .5 and the majority of over-
dispersion factors were below 2 (Figure 9).  Assuming an over dispersion of 2, in 6 
years it would be possible to detect a 6% decrease in resistance if initial resistance was 
25% and it would be possible to detect an 8% decrease in 5 years if the initial 
resistance was increased to 50%.   
The number of isolates sampled each year plays an important role in the 
power.  Power increases dramatically between 1 and 100 isolates per year.  It increases 
slowly between 100 and 500 isolates.  Beyond 500 isolates the power sharply plateaus.    
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Figure 8: Power analysis for testing changes in mean log2 MIC.  
A) Distribution of empirical standard deviation across all bacteria, drug, stage 
combinations. B) Calculation of power assuming a standard deviation of .6. C) 
Calculation of power assuming a standard deviation of 1. D) Power of a test 
comparing 9 years before a policy change with 5 years after the change as a function 
of the number of isolates sampled each year.  Dashed lines indicate a power of .8, the 
standard minimum power desired for a hypothesis test 
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Figure 9: Power analysis for testing changes in percent resistance.  
A) Distribution of empirical percent resistance across all bacteria, drug, stage 
combinations.  B) Distribution of empirical over-dispersion.  C) Plot of over-
dispersion vs. sample size D) Calculation of power assuming an initial resistance of 
25% and an over-dispersion of 2. E) Calculation of power assuming an initial 
resistance of 50% and an over-dispersion of 2. Dashed lines indicate a power of .8, the 
standard minimum power desired for a hypothesis test. 
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The above estimates assume that only one hypothesis test is being carried out 
but in practice it would be necessary to perform one test for each bacteria – drug 
combination.  In practice results would need to be adjusted to account for multiple 
testing to protect against false positives. 
Analyzing the effects of a change in enrofloxacin policy 
The exploratory analysis of the trend in C. jejuni resistance to ciprofloxacin 
shows that since the policy change in 2005 both mean log2 MIC and percent resistance 
has remained essentially constant if not slightly increasing at both slaughter and retail 
(Figure 10).   Both generalized linear models also confirm this fact (Table 4).  The t-
test of the difference in mean log2 MIC before and after the policy change is not 
significant at retail (effect=.028, p=.9) or slaughter (effect=.44, p=.13).  Removing 
approval for enrofloxacin in poultry did not decrease resistance to fluoroquinalones.  
Discussion 
Antimicrobial resistance is a growing threat with serious implications not only 
for human and veterinary health but also the food supply, animal agriculture and the 
economy.  To counteract this threat the FDA has proposed tightening restrictions on 
the use of antimicrobials.  This change however will undoubtedly have consequences 
for food production and pricing.  With this in mind it is essential to understand 
historical baseline resistance trends and to insure it will be possible to assess the 
effects of the policy change on future levels of resistance. 
The exploratory analysis undertaken here demonstrates that over the past 
decade percent resistance and mean log2 MIC at both slaughter and retail have  
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Figure 10: Exploratory assessment of the 2005 tightening of enrofloxacin policy on 
Campylobacter jejuni resistance to ciprofloxacin.   A) Boxplots of log2 Mean 
Inhibitory Concentration. The dashed line indicates the breakpoint between resistant 
and susceptible isolates.  B) Line graph of percent isolates with MIC values above the 
resistance breakpoint. Sizes of points are proportional to the number of observations in 
the given year and stage. Data from 2002 to 2003 are included in this analysis as it is 
an assessment of a 2005 policy change.  Ciprofloxacin is studied because it is the 
metabolic product of enrofloxacin. Sample sized ranged from 78 to 1348. 
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Table 4: Generalized linear modeling assessment of the 2005 tightening of 
enrofloxacin policy on Campylobacter jejuni resistance to ciprofloxacin.  
 
C. jejuni-Ciprofloxacin 
Logistic Linear 
α -1.64* -1.68* 
β2003 -0.20 -0.41* 
β2004 0.06 -0.56* 
β2005 -0.17 -0.55* 
β2006 -0.23 -0.62* 
β2007 0.12 -0.26 
β2008 0.09 -0.26 
β2009 0.28 0.13 
β2010 0.36* 0.05 
β2011 0.24 0.06 
β2012 0.21 0.00 
βSlaughter 0.14* -0.44* 
* significant at α=.05 
 
fluctuated up and down in a bacteria-drug specific manner.  The logistic and linear 
models confirm this observation as both year and stage coefficients were significant in 
likelihood ratio tests.  While logistic and linear models reveled the same overall 
trends, each model provides a distinctly useful lens on AMR.  Logistic regression 
provides a straightforward characterization of situations where there is a known 
epidemiological cutoff or clinical breakpoint between resistance and susceptibility. 
Logistic regression however is highly sensitive to the choice of breakpoint making it 
opaque to interpret when the resistance threshold is difficult to determine (Jaspers 
2014).  In this case linear regression of log2 MIC provides a more straightforward 
characterization of resistance patterns.  Additionally, because linear regression 
explains the mean resistance level, it can in general provide a more holistic lens on 
AMR.   
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Mixed effects models show that there are different levels of variation between 
and within years.  Surprisingly however there is more variation within years than 
between years and accounting for state does little to resolve this variation. This 
indicates that most of the AMR variation is due to the structure of resistance in the 
population. 
Our analysis showed that by performing a hypothesis test comparing the level 
of resistance before and after a change it is possible to detect a change in resistance 
level as small as 1 log2 MIC in 5 years or a 6% change in resistance in as little as 6 
years.  Moreover, the current 200 isolates per year level of data collection provides 
more than sufficient power and could in fact be reduced to 100 samples per year 
without significant reduction in power.  Although it might be interesting to test the 
change in slope of the trend line before and after a policy change, our exploratory 
analysis showed that resistance patterns do not often have clear trends and so we chose 
to focus on a comparison test of resistance levels.  Even though it would take 6 years 
to detect a change in AMR after the new level had been reached, which may itself take 
several years, this is a fairly short period of time on a policy making scale.  As a result, 
even though it may be difficult to predict the outcome of the current change in FDA 
policy it will not be difficult to assess changes on AMR. An implicit assumption of the 
proposed approach is that changes on the AMR levels after the policy implementation 
can be attributable largely to the policy. A combined analysis of the antimicrobial use 
and resistance would provide a greater level of evidence (EFSA, 2006). However, in 
United States, antimicrobial use data are limited to sales of active compounds 
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aggregated by drug class intended for use in all food-producing animals since 2009 
(FDA, 2013b). 
Analyzing the change on resistance before and after implementation of 
enrofloxacin policy reveals the complexities of managing and evaluating AMR. To the 
extent that there was a trend AMR increased following the policy change but this was 
not significant even for log2 MIC which provides a more sensitive test.  Previous 
studies aiming to evaluate the enrofloxacin ban reported unchanged resistance levels 
for ciprofloxacin in Campylobacter isolates recovered from chicken and chicken 
carcasses (Nannapaneni, 2009; Price 2007). These previous surveys sampled a small 
number of isolates during short periods of time (2004 to 2006) and narrow 
geographical locations. Based on our analysis, AMR changes during short time spans 
(e.g. 2 years) are unlikely to show changes on AMR levels even if the policy was 
effective.  A more comprehensive study analyzed changes on the proportion of 
resistant isolates to ciprofloxacin for Campylobacter in the NARMS retail meat 
samples from 2002 to 2007, and found no changes (Zhao, 2010).  
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CHAPTER 3 
 
INFERRING THE INTERACTION STRUCTURE OF RESISTANCE TO 
ANTIMICROBIALS  
Introduction 
Antimicrobial resistance is a serious threat to human and animal health 
garnering much attention domestically and internationally.  According to the CDC, in 
the US more than 2 million people a year contract an antibiotic resistant infection. In 
the EU more than 25,000 people a year die due to antibiotic resistant bacteria, based 
on data from the European Commission Directorate-Generals on Health and Food 
Safety.  In 2011 The EU issued an action plan on antibiotic resistance, and the US 
followed suit in 2015. Within the domain of antibiotic resistance an especially 
concerning problem is that of multi-drug resistance as it may increase the chances that 
there will be no therapeutic agent available to treat a given infection.  It is therefore 
essential to understand not only resistance, but the dynamics of multi-drug resistance. 
To gain a more complete picture of multi-drug resistance it is important to 
interrogate the associations between the various drug resistances.  Associations can 
have clinical as well as mechanistic consequences.  In the clinical setting they could be 
used in recommending courses of treatment for an infection that is not responding to a 
particular antibiotic.  They could also be used in designing antimicrobial cocktails.  
Beyond the clinic, associations between resistances may shed light on underlying 
mechanisms.  A group of drugs that are always susceptible together or always resistant 
together may indicate that the resistance is due to a common underlying biological 
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mechanism.  More complex associations may indicate linkage between resistance 
genes or linkages in the selection pressures occurring because drugs are often present 
in the same environment. 
  Inferring associations between resistances can be accomplished by comparing 
the probability of resistance under various combinations of the resistance status of 
other drugs.  If, as shown in Table 1a, a microbe is resistant to drug X 10 out the 200 
or 5% of the time when it is susceptible to drug Y, but 100 out of the 200 or 50% of 
the time when it is resistant to drug Y, then we can conclude there is a 2-way 
association between drugs X and Y. Such associations can be visualized using a 
network or graph with drugs as nodes and edges between drugs that share a 2-way 
association.  By looking at combinations of resistance and susceptibility for multiple 
microbes we can infer associations between more than two variables. This is the case 
in Table 1 if Table 1a is taken to be data for microbes susceptible to drug Z and Table 
1b is taken to be microbes resistant to drug Z.  In Table 1a, among isolates that are 
susceptible to drug Z, a microbe is resistant to drug X 5% of the time when it is 
susceptible to drug Y and 50% of the time when it is resistant to drug Y.  In Table 1b, 
among isolates resistant to drug Z, a microbe is resistant to drug X 185 out of 200 or 
92.5% of the time when it is susceptible to drug Y and 4 out of 4 or 100% of the time 
when it is resistant to drug Y.  Since drug Z modifies the relationship between drugs X 
and Y we conclude there is a 3-way association between drugs X, Y, and Z.  When 
there is an association involving more than 2 drugs it is called an interaction.  
Previous studies have examined the 2-way association structure of multidrug 
resistance.  Additive Bayesian models were applied to examine 2-way associations in 
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resistance of Escherichia coli isolated from pig pens in Canada (Lugwig et al., 2013).  
Graphical models have been used to examine the dependence structure of E. coli 
isolated from chicken at slaughter and retail stages in the US (Love et al., 2016).  Both 
studies determined that multidrug resistance is highly structured with dependences 
between antibiotics in the same drug class as well as between classes.  In particular 
Love et al. (2016) identified two subnetworks, one for the β-lactams and a second 
covering a mixture of drug classes.  These studies also showed that these dependences 
are supported by known biological mechanisms.  An example is associations between 
drugs that are known to be degraded by β-lactamases.  Another example is 
associations between drugs for which resistance genes are known to be carried on the 
same plasmid. 
Pairwise associations capture much of the clinically relevant information as 
they reveal the major connections between the drugs.  However, they are less helpful 
in shedding light on underlying mechanism as they do not reveal more complex 
relationships (interactions) involving multiple drugs. With this in mind this paper 
examines the interaction structure of antibiotic resistance. It does so by making use of 
log-linear models for contingency tables, exact conditional testing, and Bayesian 
inference. 
Materials and Methods 
The dataset 
 One of the most comprehensive sources of data on antimicrobial resistance in 
the United States is that collected by the National Antimicrobial Monitoring System 
(NARMS).  Since 1996, NARMS, a collaboration among the United States 
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Department of Agriculture, Food and Drug Administration and Center for Disease 
Control and Prevention, has been monitoring antimicrobial resistance in slaughter 
houses, retail meat, and human enteric bacteria.  It monitors antibiotic resistance of 
Escherichia, Enterococcus, Campylobacter and Salmonella isolated from beef, 
chicken, turkey and pork at slaughter and retail.  Resistance is also monitored in 
human enteric Campylobacter and Salmonella.  NARMS reports resistance as 
minimum inhibitory concentrations along with guidelines for setting resistance 
thresholds. 
For the purposes of this study the publically available data sheets were 
downloaded from the NARMS website.  Susceptibility status was determined using 
the NARMS guidelines.  The dataset consisted of slaughter and retail data from the 
years 2011 through 2013 as these were the three most recent years for which there 
were data at both stages.  Chicken was chosen as the host and E. coli as the bacteria 
since this maximized sample size.  In order to appear in the analysis a drug had to be 
present in more than 80% of all samples, and a sample had to be tested for each such 
drug.   All analyses were carried out in Python (Van Rossum, 1995). Regressions were 
done using the Statsmodels package (Seabold, 2010).  Hypothesis tests were done 
using Scipy (Perez, 2011). 
Log linear model 
 One standard way to infer interactions like that in Table 1 is using log-linear 
models for contingency tables (Agresti, 2002, pp. 314).  In these models the expected 
count in each cell of the table is modeled as a function of the resistance and  
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Table 1: Hypothetical contingency tables representing the counts for various 
susceptible/resistant (S/R) combinations of three drugs X, Y and Z.  Table 1a is for 
when drug Z is susceptible and Table 1b is for when drug Z is resistant.  
a.) 
Y 
S R 
X 
S 190 100 
R 10 100 
 
 
susceptibility pattern among the drugs. For example, if there are three drugs (X, Y and 
Z), the most general model is given by equation 1 
log ( ' = ` + `a +  `b + `'c + ` ab + `'ac +  `'bc + ` 'abc        (1) 
where ( is the expected cell count, and the indices, i, j, k, take values 1 and 2 for 
susceptible and resistant, respectively.  In order for the model to be identifiable, all 
parameters with a 1 subscript are set to zero. The parameter ` is then the log expected 
cell count of cell 111. The last coefficient in the model is the difference in the log 
odds-ratio for the two partial tables for X and Y, one when Z is resistant and one when 
Z is susceptible. This coefficient is zero only if there is no 3-way interaction. 
  Inference concerning coefficients in log-linear models is typically done by 
fitting the model via maximum likelihood, and then testing hypotheses about 
coefficients using likelihood-ratio or Wald statistics. The null distributions of these 
test statistics are approximately chi-squared provided most of the counts in the 
contingency table are not too small. For example, a rule of thumb that is often used 
b.) 
Y 
S R 
X 
S 15 0 
R 185 4 
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when testing for association in a 2 by 2 table is that all the estimated expected counts 
should be at least 5 (Cochran, 1954). Unfortunately, this assumption is often violated 
in our data.  One example of this is a four-way interaction among amoxicillin-
clavulanic acid, ceftriaxone, cefoxitin, and ceftiofur for which the contingency table is 
shown in Table 2.  In these cases the interactions will not be reflected in the log-linear 
model fit.  Table 3 shows this for the simpler case of drugs X, Y and Z, where the 
interaction term is not significant. This is due to the failure of the chi-squared 
approximation to the null distribution of the Wald statistic caused by the low counts 
(and some zeros) in the contingency table. 
Exact conditional testing 
The most common way to overcome violations of the large expected counts 
assumption necessary for asymptotic inference concerning coefficients in log-linear 
models is to carry out an exact conditional test.  The simplest and most famous 
example of an exact test for associations in a contingency table is Fisher’s exact test 
for two-way associations between binary variables (Fisher, 1935; Irwin, 1935).  
Consider a general 2-way table like that of Table 4.  If the row and column sums are 
fixed, the entire table can be determined from a single known cell value. Assuming 
multinomial sampling, if there is no association between the two variables, the count 
in the (1,1)-cell has a hypergeometric distribution given in equation 2. 
XN:O = <^.L^LLA< ^.>^L.R^LLA∑ 0^.Lf 7< ^.>^L.RfA]fgh         (2) 
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Table 2: Contingency table for the four-way interaction among amoxicillin-clavulanic 
acid, ceftriaxone, cefoxitin, and ceftiofur.  S signifies susceptible and R signifies 
resistant. 
Ceftiofur=S 
Amoxicillin-Clavulanic Acid 
S 
 
R 
 
Cefoxitin 
 
Cefoxitin 
S R S R 
C
ef
tr
ia
xo
ne
 
S 2437 3 
C
ef
tr
ia
xo
ne
 
S 5 13 
R 3 0 R 2 24 
 
Ceftiofur=R 
Amoxicillin-Clavulanic Acid 
S 
 
R 
 
Cefoxitin 
 
Cefoxitin 
S R S R 
C
ef
tr
ia
xo
ne
 
S 0 0 
C
ef
tr
ia
xo
ne
 
S 0 0 
R 3 0 R 1 200 
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Table 3: Results of fitting a log-linear model to the three-way contingency table for 
hypothetical drugs X, Y and Z. 
 
Coefficient 
Standard 
Error p-value 
Intercept 5.247 0.0726 <.000001 
X -2.944 0.324 <.000001 
Y -0.642 0.124 <.000001 
Z -2.539 0.268 <.000001 
X:Y 2.944 0.354 <.000001 
X:Z 5.457 0.421 <.000001 
Y:Z -24.37 4,225 1.0 
X:Y:Z 18.23 4,225 1.0 
 
 
 
 Table 4: Notation for a generic contingency table.  S signifies susceptible and R 
signifies resistant. 
 
Y 
S R  
X 
S n11 n12 n1. 
R n21 n22 n2. 
 n.1 n.2 n.. 
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where  = maxN0, :. + :. − :..O and ℎ = minN:., :.O.  The p-value for Fisher’s 
exact test is usually defined as the cumulative probability of all tables as or less 
probable than the one we observed.  The logic of this test can be extended to test for 
three way interactions as long as we fix the additional margin so that the entire table 
can be determined from a single cell count value. The null distribution for this test, a 
special case of Zelen’s test for no interaction in a 2x2xK table (Zelen, 1971), is given 
in equation 3.   
XN:O = <^.LL^LLLA< ^.>L^L.LR^LLLA< ^.L>^LL.R^LLLA< ^.>>^L.>R^LL.o^LLLA∑ 0^.LLf 7< ^.>L^L.LRfA< ^.L>^LL.RfA< ^.>>^L.>R^LL.ofA]fgh         (3) 
where	 = 	maxN0, :.+:.−:.., :.+:.−:.., :.+:.−:..O and ℎ =
minN:., :., :., :.+:.+:.−:..−:..−:..+:…O.  These bounds arise from 
applying the bounds in Fisher’s exact test to the 2x2 “slices” that contain the 111 and 
112 cells. 
 While exact conditional tests can be used even if some of the counts are small, 
in extreme situations conditioning on the table margins can remove the information 
about the association of interest. For example, there are only 5 tables with the same 
marginal totals as the 2x2x2 table given in Table 1. In this instance the 111 cell can 
take values 190 to 194, and the observed value, 190, has the highest null probability 
equal to 0.983. Clearly this “exact” test fails to reject the hypothesis of no interaction. 
A Bayesian approach 
 To address the problems that result from conditioning on all of the table 
margins we propose a Bayesian test conditioned only on the total number of 
observations. Conditional on the total number of observations the vector of cell counts 
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in the contingency table is a multinomial variable with cell probabilities q '.  The 
conjugate prior for the multinomial distribution is the Dirichlet distribution (Kotz et 
al., 2000, pp. 485). This implies that the posterior distribution of the vector of cell 
probabilities also has a Dirichlet distribution. For example, in the 3-way table case, 
with prior concentration parameters r ', the posterior distribution is given by 
equation 4. 
X0qsr, : '7 = t0∑ 0GPSWP7uvw 7∏ t0GPSWP7uvw ∏ q 'GPSWPyz{         (4) 
That is, the posterior concentration parameters are the sum of the prior values and their 
corresponding cell counts. In our analyses, we use an uninformative Dirichlet prior 
with concentration parameters all set to 1, or equivalently a uniform distribution over 
the K-dimensional simplex, where K is the number of drugs under consideration. 
The posterior distribution of any function of the cell probabilities can be 
estimated based on 1 million draws from this Dirichlet distribution. For example, to 
test for interaction in a 3-way table we can estimate the posterior distribution of the 
interaction coefficient 
` 'abc = ! <|LLL|>>L|>LL|L>LA − ! <|LL>|>>>|>L>|L>>A        (5) 
and determine if 0 is a plausible value.  The posterior distribution for the three-way 
interaction in table 1 is given in Figure 1 and shows that the Bayesian procedure is 
able to detect this interaction because the entire posterior distribution of the interaction 
coefficient lies to one side of 0. In what follows we define the significance of a 
coefficient as 1 minus the coverage of the largest posterior credible interval that does  
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Figure 1: Posterior distribution of the interaction coefficient of hypothetical drugs X, 
Y and Z. 
 
not contain 0.  We choose .01 as our significance threshold to account for multiple 
testing, but many of the probabilities are substantially lower. 
Results 
We first tested all possible pairs of drugs using the Dirichlet-multinomial model 
described above.  At the .01 significance threshold, there was an association between 
almost every pair of drugs.  Lowering the threshold to .00001 provides a more 
informative picture of the pairwise associations and results in the graph in Figure 2.  
This graph suggests that dependences between the drugs can be decomposed into two 
dense sub-networks with a few ancillary drugs, a finding consistent with that of Love 
et al., (2016). The first subnetwork consists of the β-lactams ampicillin, ceftriaxone,  
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Figure 2: Pairwise associations between antibiotics.  This network can be decomposed 
into 2 subnetworks, the one of the left composed of β-lactams the other composed of a 
mixture of drug classes. 
 
cefoxitin, amoxicillin-clavulanic acid, and ceftiofur, as well as the phenicol 
chloramphenicol.  The second subnetwork bridges from chloramphenicol and 
ampicillin to the aminoglycosides streptomycin, gentamicin, and kanamycin, 
tetracycline, and the sulfonamides sulfisoxazole and trimethoprim-sulfamethoxazole.  
Additionally, the macrolid azithromycin is attached to trimethoprim-sulfamethoxazole 
alone and the fluoroquinolones nalidixic acid and ciprofloxacin are connected to one 
another.  The dense structure of each of the subnetworks suggests they might contain 
multi-drug interactions.  These subnetworks are small enough that it is feasible to test 
all possible interactions within each of them. 
The first sub-network is characterized by a significant β-lactam only four-way 
interaction among amoxicillin-clavulanic acid, ceftriaxone, cefoxitin and ceftiofur 
with posterior probability 0.00583.  This interaction results from a hierarchy where the 
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resistance status of amoxicillin-clavulanic acid, ceftriaxone, and cefoxitin are 
generally identical and susceptibility to any of these three implies susceptibility to 
ceftiofur.  The near equivalence among amoxicillin-clavulanic acid, ceftriaxone, and 
cefoxitin is shown in Table 5 with almost all isolates being susceptible to all three 
antibiotics or resistant to all three antibiotics.  The hierarchical relationship among 
amoxicillin-clavulanic acid, ceftriaxone, and ceftiofur can be seen in Table 6 where 
isolates susceptible to amoxicillin-clavulanic acid or ceftriaxone are almost always 
susceptible to ceftiofur.   
The second subnetwork is characterized by 2 four-way interactions and 10 
three-way interactions that are not contained in a four-way interaction as shown in 
Table 7.  All of these interactions include at least 2 different antibiotic classes.  Both 
four way interactions involve 4 different drug classes, the aminoglycoside gentamicin, 
tetracycline, the β-lactam ampicillin, and a sulfonamide either trimethoprim-
sulfamethoxazole or sulfisoxazole. Many of the three factor interactions are also 
among 3 different drug classes for example the interaction among the aminoglycoside 
streptomycin, the sulfonamide sulfisoxazole and tetracycline.  The contingency tables 
underlying these interactions, like that for the streptomycin:sulfisoxazole:tetracycline 
interaction shown in Table 8, tend to have more nuanced count patterns than the all or 
nothing hierarches of the β-lactam interaction. 
Discussion 
Three approaches to interaction testing 
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The results of applying the three different approaches to inferring higher order 
interactions reveal the strengths and weaknesses of these different methods as well as 
some unique features of antibiotic co-resistance relationships.  
The inability of approximate chi-squared tests to detect obvious relationships like that 
among amoxicillin-clavulanic acid, ceftriaxone, cefoxitin and ceftiofur highlights the 
sensitivity of such approximations to zero (and small) cell counts. The failure of exact 
testing to detect the interaction is due to the severe restriction on the sample space 
imposed by conditioning on table margins in extremely sparse contingency tables. In 
such cases, the margins of a contingency table can contain some of, and possibly all, 
the information about associations. The Bayesian approach by contrast side steps both 
problems and leads to robust inferences based on exact marginal posterior 
distributions.  This approach has clear advantages in terms of making the inference 
possible in this setting. The method does require sampling from the posterior 
distribution for each interaction that is tested. However, this is straightforward in this 
setting because the posteriors are all Dirichlet distributions that are easy to simulate 
from. 
The small cell counts and restrictions on sample space that plague the 
approximate and exact conditional methods have a common source fundamental to 
antimicrobial resistance.  They arise from structured relationships between antibiotics 
like the hierarchy among the β-lactams.  These relationships make some resistance 
combinations extremely rare and create cells and sometimes even marginal counts that 
are near zero. 
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Table 5: Contingency table showing the equivalency among amoxicillin-clavulanic 
acid, ceftriaxone, and cefoxitin.  Almost all isolates are either susceptible to all three 
drugs or resistant to all three.  S signifies susceptible and R signifies resistant. 
Amoxicillin-Clavulanic Acid 
S 
 
R 
 
Cefoxitin 
 
Cefoxitin 
S R S R 
C
ef
tr
ia
xo
ne
 
S 2437 3 
C
ef
tr
ia
xo
ne
 
S 5 13 
R 6 0 R 3 224 
 
Table 6: Contingency table showing the hierarchy among amoxicillin-clavulanic acid, 
ceftriaxone, and ceftiofur.  Almost all isolates susceptible to either amoxicillin-
clavulanic acid or ceftriaxone are also susceptible to ceftiofur.  S signifies susceptible 
and R signifies resistant. 
Amoxicillin-Clavulanic Acid 
S 
 
R 
 
Ceftiofur 
 
Ceftiofur 
S R S R 
C
ef
tr
ia
xo
ne
 
S 2440 0 
C
ef
tr
ia
xo
ne
 
S 18 0 
R 3 3 R 26 201 
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Table 7: Significance of interactions underlying a multi-drug resistance subnetwork 
composed of several antibiotic classes.  A) Four-way interactions. B) Three-way 
interactions not part of a four-way interaction. 
A) 
Interaction 
Significance 
Level 
Gentamicin:Sulfisoxazole:Tetracycline:Ampicillin 0.000070 
Trimethoprim-Sulfamethoxazole:Gentamicin:Tetracycline:Ampicillin 0.00444 
 
B) 
Interaction 
Significance 
Level 
Gentamicin:Streptomycin:Tetracycline <.000001 
Streptomycin:Sulfisoxazole:Tetracycline <.000001 
Gentamicin:Streptomycin:Ampicillin <.000001 
Gentamicin:Sulfisoxazole:Kanamycin 0.0000340 
Trimethoprim-Sulfamethoxazole:Streptomycin:Tetracycline 0.0000560 
Streptomycin:Sulfisoxazole:Chloramphenicol 0.00155 
Tetracycline:Kanamycin:Ampicillin 0.00183 
Gentamicin:Tetracycline:Ampicillin 0.00528 
Streptomycin:Sulfisoxazole:Kanamycin 0.00703 
Sulfisoxazole:Tetracycline:Kanamycin 0.00799 
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Table 8: Contingency table for the three-way interaction among streptomycin, 
sulfisoxazole, and tetracycline.  All cell counts in this table are large indicating a non-
hierarchical relationship between these 3 drugs.  S signifies susceptible and R signifies 
resistant. 
Streptomycin 
S 
 
R 
 
Tetracycline 
 
Tetracycline 
S R S R 
S
ul
fi
so
xa
zo
le
 
S 883 292 
S
ul
fi
so
xa
zo
le
 
S 138 133 
R 131 208 R 357 549 
  
 
The structure of multi-drug resistance 
Application of the Bayesian test reveals that patterns of multidrug resistance 
can be broken down into two sub-networks with two distinct sets of features.  One 
subnetwork consists of a single antibiotic class and has an interaction structure that 
results from a hierarchical relationship.  The other contains a number of antibiotic 
classes.  The interactions in this subnetwork are all between antibiotic classes and are 
characterized by dense contingency tables with more subtle patterns to their counts. 
The β-lactam sub-network 
All of the drugs in the first network are β-lactams with the exception of 
chloramphenicol which primarily serves to connect this subnetwork with the second 
subnetwork.  β-lactams are antibiotics that work by inhibiting the synthesis of 
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peptidoglycan, which is necessary for, among other things, constructing the bacterial 
cell wall (Brunton, 2011, pp. 1480).  This subnetwork is underpinned by a single β-
lactam only interaction resulting from a hierarchy in which amoxicillin-clavulanic 
acid, ceftriaxone, cefoxitin, have nearly identical resistance patters and susceptibility 
to any one of these three implies susceptibility to ceftiofur.  This hierarchy is in 
agreement with the known pharmacology of these drugs.  The first tier of antibiotics is 
composed of drugs that are not affected by the presence of β-lactamases, enzymes 
focused on metabolizing β-lactams.  Amoxicillin-clavulanic acid explicitly contains 
the -lactamase inhibitor clavulanic acid and ceftriaxone as well as cefoxitin are 
known to be inherently resistant to -lactamases (Brunton, 2011, pp. 1480).  The 
second tier, ceftiofur, has the least amount of resistance of the -lactams in this 
dataset. 
The other sub-network 
The second sub-network is made up of aminoglycosides which inhibit protein 
synthesis by binding to the 30S ribosomal subunit, tetracycline which also functions 
by binding to the ribosome but binds specifically to the A site, phenicols which inhibit 
ribosomal peptydal transferase activity, sulphafonamids which inhibit folate synthesis 
and -lactams (Brunton, 2011).  The fact that the interactions in this subnetwork link 
such disparate antibiotic functions make it unlikely that they result from a single 
pharmacological mechanism like the -lactam subnetwork. Also, while multi-drug 
resistance can result from pumps that move a number of antibiotics out of the bacterial 
cytoplasm (Brunton, 2011, 1480) the large difference in the structures of the linked 
antibiotics make this unlikely. 
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Two mechanisms that could explain the interactions in this second network are 
linked genes and linked selection pressures.  Integrons could very easily link together 
genes for resistance to different antibiotic classes.  In fact, some of the inferred 
linkages such as that between sulfisoxazole and streptomycin and are known to be 
present in integrons (Fluit, 2004).  The dense nature of the contingency tables for these 
interactions would naturally result from a large variety of resistance cassettes with 
overlapping patterns of genetic linkage.  These patterns could also result from many 
overlapping hierarchies of antibiotic administration as an ensemble of clinicians 
respond to developing patterns of multidrug resistance. 
Comparison to previous work 
 In this paper, we take a log-linear model approach to explore interactions 
among the resistance or susceptibility of various antibiotics.  Love et al. (2016) 
applied the graphical lasso to continuous minimum inhibitory concentration values 
from a similar dataset to create networks of dependencies between drugs.  This study 
similarly found that the dependencies could largely be divided into two sub-networks, 
one for the -lactams and another for the other drugs.  The main difference between 
the two resulting networks is that the ones presented here are much denser.  This may 
be the result of differences in the effective significance level of the two tests.  While 
the hypothesis testing approach employed here uses an explicit 1% significance level 
the graphical lasso relies on a tunable parameter to determine how sparse or dense the 
resulting network should be.  
Conclusion 
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 Antibiotic resistance is a serious health threat that has captured the attention of 
politicians, regulators and clinicians.  Even more threating than the development of 
resistance to a single antibiotic is the development of simultaneous resistance to 
multiple drugs as it increases the likelihood of an infection that cannot be treated with 
any known antibiotic.  To understand these multidrug resistances, we must understand 
the various interactions that characterize them.  By employing a Bayesian hypothesis 
testing approach, we have explored not only the pairwise associations but also the 
interactions involving three or more drugs.  This analysis has revealed that multidrug 
resistance is characterized by a broad range of interaction patterns. One example 
involves a clear-cut and biologically meaningful hierarchical relationship in a single 
drug family.  This relationship creates an extreme sparsity pattern that cannot be 
analyzed using standard asymptotic chi-squared tests or even exact conditional tests, 
but which can be detected using a Bayesian approach described in this paper. In other 
cases the interaction pattern is more complex, with overlapping sets of antibiotics from 
a variety of drug classes.  These results validate concerns over the complex etiology of 
multidrug resistance.  They also suggest the need for detailed population genetic 
studies to tease apart their molecular underpinnings so that the extent of multidrug 
resistance can be controlled. 
 
 
 
 
 
 68 
REFERENCES 
Print References 
Agresti, A., 2002. Catagorical Data Analysis, 2nd edition. John Wiley & Sons, 
Hoboken, New Jersey.  
Brunton, L. L., Chabner, B.A., Knollmann, B. C., 2011. Goodman and Gilman’s the 
pharmacological basis of therapeutics, 12th edition. McGraw Hill Medical, New York, 
New York. 
Cochran, W. G., 1954. Some methods of strengthening the common chi-square tests. 
Biom. 10, 417-451. 
European Commission Directorate-General for Health and Consumers., 2011, Action 
plan against the rising threats from antimicrobial resistance. 
Fisher, R. A., 1935. The logic of inductive inference. J. of the R.  Stat. Soc. Ser. A. 98, 
39–54. 
Fluit, A. C., Schmitz, F. J., 2004. Resistance integrons and super-integrons. Clin. 
Microbiol. Infect. 10, 272–288.  
Irwin J. O., 1935. Tests of significance for differences between percentages based on 
small numbers. Metron. 12, 83–94. 
Kotz, S., Balakrishnan, N., Johnson, N. L., 2000. Continuous Multivariate 
Distributions. Volume 1: Models and Applications. John Wiley & Sons,  New York. 
Love, W. J., Zawack, K. A., Booth, J. G., Grohn, Y. T., Lanzas, C., 2016. Markov 
Networks of Collateral Resistance: National Antimicrobial Resistance Monitoring 
System Surveillance Results from Escherichia coli Isolates, 2004-2012. PLoS. 
Comput. Biol. 12(11), e1005160. doi:10.1371/journal.pcbi.1005160. 
 69 
Ludwig, A., Berthiaume, P., Boerlin, P., Gow, S., Léger, D., Lewis F.I., 2013. 
Identifying associations in Escherichia coli antimicrobial resistance patterns using 
additive Bayesian networks. Prev. Vet. Med. 110, 64-75. 
http://dx.doi.org/10.1016/j.prevetmed.2013.02.005. 
Perez, F., Granger, B. E., Hunter, J. D., 2011. Python: An Ecosystem for Scientific 
Computing. Comput. in Sci. Eng. 13, 2, 13-21. 10.1109/MCSE.2010.119. 
Seabold, S. Perktold, J., 2010. Statsmodels: Econometric and statistical modeling with 
python. Proc. of the 9th Python in Sci. Conf. 
Van Rossum, G., 1995. Python tutorial. Technical Report CS-R9526, Centrum voor 
Wiskunde en Informatica (CWI). 
 White House, 2015, National action plan for combating antibiotic-resistant bacteria. 
Zelen, M., 1971. The Analysis of Several 2x2 Contingency Tables. Biom. 58, 129–
137. 
Web References 
CDC. https://www.cdc.gov/drugresistance. 11-25-2016 
European Commision Directorate-Generals on Health and Food Safety. 
http://ec.europa.eu/dgs/health_food-safety/amr/index_en.htm, 11-25-2016 
[Dataset] National Antimicrobial Monitoring system. 
http://www.fda.gov/AnimalVeterinary/SafetyHealth/AntimicrobialResistance/National
AntimicrobialResistanceMonitoringSystem/ucm416741.htm. 11-25-2016 
 70 
CHAPTER 4 
 
ANALYSIS OF VARIATION IN MULTIDRUG INTERACTIONS INFERED 
BASED ON THE NATIONAL ANTIMICRIBIAL MONITORING SYSTEM 
Introduction 
Antimicrobial resistance develops through evolution.  Resistance traits enter a 
population through mutation and gene transfer and then grow or shrink in proportion 
based on the fitness of the organisms that possess them.  As such antimicrobial 
resistance is affected by the myriad variables that influence microbial fitness. This 
includes factors related to antimicrobials such as the amount of antimicrobials present, 
but also factors unrelated to antimicrobials like the available carbon source. This 
makes it difficult to make sense of long term trends in resistance as latent variables 
inflate the variation in measured resistance.  The problem can be compounded in 
surveillance programs that cover large geographic areas and long periods of time.  In 
the United States such surveillance is carried out by the National Antimicrobial 
Monitoring System (NARMS).  Analysis of resistance to single antibiotics in the 
NARMS data set has shown significant amounts of over dispersion (Zawack, 2016).  
More concerning to public health than resistance to a single antimicrobial is 
simultaneous resistance to multiple antimicrobials.  This paper examines the variation 
in the NARMS dataset, focusing on multidrug resistance variation in the animal 
production surveillance components. 
There are many factors that can potentially influence antimicrobial resistance.  
Beginning on the farm resistance may be influenced by the particular husbandry 
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practices.  Cow-Calf farms have been shown to have different levels of resistance than 
feed lots (Carson, 2008) and differences in resistance patterns have been detected 
among dairy, beef, and veal farms (Catry, 2016).  Also, organic production processes 
have been shown to have lower resistance levels than conventional approaches 
(Miranda, 2008).  Husbandry practices may also interact with animal age as some 
authors have found increases in resistance with age for cattle (Carson, 2008) while 
others have found decreases (Gow, 2008).  Moreover, because there is evidence that 
animal microbiomes change over time (Holman, 2015), resistance may also be 
affected by the particular microbial make up of a given environment.  In light of this, 
resistance would then be affected by any factor that influences the microbe content of 
an environment, such as temperature, moisture, and nutrient sources.  At slaughter 
such a dependency on microbe content indicates that resistance may be influenced by 
overall hygiene (Lerma, 2014a).  Additionally, specific hygiene practices can also 
influence resistance as analyses of genetic relatedness of bacteria in different locations 
in a slaughterhouse indicate that many of the bacteria throughout the slaughter facility, 
including those on products headed to retailers, come directly from the live animals 
(Lerma, 2014b).  Disinfectant usage may also affect resistance.  These effects may be 
indirect, by affecting general microbial ecology, or more direct, through linkages 
between antimicrobial resistance and disinfectant resistance (Lerma, 2015).  These 
factors are likely to play similar roles in retail facilities. 
NARMS has three components, two covering animal production, and a third 
covering human medicine (NARMS, 2016). The first animal production component 
monitors animal slaughter facilities and the second monitors retail meat.  The 
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slaughter facility surveillance obtains its samples from the food safety monitoring of 
slaughter houses carried out by the United States Department of Agriculture’s Food 
Safety Inspection Service (FSIS).  Food safety, not antimicrobial resistance is the 
mandate of FSIS, so its sampling procedures are targeted not at resistance 
surveillance, but at food safety and change as these food safety needs change.  The 
slaughter component of NARMS began in 1997.  At that time most isolates came from 
random inspections that sampled each facility almost every year.  A small proportion 
of isolates came from follow-up inspections of facilities that failed initial inspection.  
There is no data available on which isolates were obtained from which regime. 
Beginning in 2006 FSIS adopted a risk based approach to focus on facilities with 
higher rates of salmonella contamination. FSIS data contains information on year, host 
animal, bacteria, antibiotic, minimum inhibitory concentration as a measure of 
resistance and that the isolate came from FSIS sampling.  There is no data about how 
the animals were raised or about the hygiene processes in the slaughter house.  The 
collection of retail samples is carried out through FoodNet, a collaboration of federal, 
state and local food safety officials. In contrast to the slaughter program the retail 
program is focused solely on antimicrobial resistance surveillance.  Retail surveillance 
began in 2001 at Connecticut, Georgia, Maryland, Minnesota, New Mexico, Oregon, 
Tennessee, California, Colorado, and New York.  It has since expanded to include 
Louisiana, Missouri, Pennsylvania, Washington, Iowa, Kansas, South Dakota, and 
Texas.  Each Foodnet site selects samples by dividing the zip codes within fifty miles 
into 4 quadrants and randomly assigning the quadrants across the months.  Each 
month a list of grocery stores is randomly selected from the assigned quadrant and a 
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total of 40 meat products are sampled from these stores.  Retail data contains 
information on state, year, host animal, bacteria, antibiotic, minimum inhibitory 
concentration and that the isolate came from retail sampling.  There is no data about 
which slaughter facility the meat came from or about the hygiene processes at the 
store. 
Antibiotic resistance is problematic because it weakens our arsenal to cure 
infections.  Multidrug resistance is even more significant because it represents a 
compound weakening of this arsenal.  One way to quantify multidrug resistance is to 
categorize each isolate as susceptible or resistant to each drug and then organize these 
isolates into a multiway contingency table.  This approach has been used in the 
previous chapter to investigate the structure of multidrug resistance.  In addition to 
many others, associations were found among gentamicin, sulfisoxazole, tetracycline 
and ampicillin. 
Here we assess the variability of multidrug resistance in the NARMS dataset.  
We do this by examining contingency tables categorizing gentamicin, sulfisoxazole, 
tetracycline and ampicillin resistance of Escherichia coli isolates sampled from 
chicken at slaughter and retail. We also examine effects of this variability on the 
inference of associations between drug resistances to uncover potential improvements 
to the NARMS system. 
Materials and Methods 
The data 
For the purposes of this study the publicly available data sheets for the 
slaughter and retail surveillance were downloaded from the NARMS website. In order 
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to account for variability due to host and bacteria type we focus here on a single host 
and bacterial species. Chicken was chosen as the host and E. coli as the bacteria 
because this maximized sample size.  We focus on the drugs gentamicin, 
sulfisoxazole, tetracycline and ampicillin, because susceptibility and resistance to 
these drugs were previously observed to be associated with one another (Zawack, 
2016; Love 2016).  These choices produced a dataset covering the years 2004 to 2012.  
Susceptibility status was determined using the NARMS guidelines.  In order to appear 
in the analysis a sample had to be tested for each of these drugs.  The processed data 
then consisted of a table with isolates as the rows and antimicrobial resistance test 
results as well as the year and production stage of the isolate in the columns.  These 
data were then in turn organized into contingency tables giving the count of isolates 
with each resistance pattern for a given setting of year and stage.  All data processing 
and analyses were carried out in Python (Van Rossum, 1995), using the Scipy package 
(Perez, 2011) for statistical analyses. 
Analysis of variation in contingency table cell counts 
 The most general type of variability in the data is the variability between 
contingency tables.  A higher than expected level of variability could result from 
systematic trends over time, or excess variation (overdispersion) due to unaccounted 
for factors like hygiene practices.  To test whether the differences in contingency table 
counts between years was in accord with random multinomial variation with no time 
trend we compared the cell frequencies from individual years with the aggregate 
frequency over all years.  Specifically we calculated the Pearson goodness-of-fit 
statistic (Agresti, 2002, pp.22) 
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where q is an estimated cell proportion, and compared it to a chi-squared distribution 
with NT − 1O x NKT − 1O degrees of freedom. We did this for slaughter data 
alone, retail data alone, and the full data set. Large values of the Pearson statistic 
provide evidence of lack-of-fit (relative to no trend) or overdispersion due to 
unaccounted for factors.  
Overdispersion with respect to univariate measures 
 It is difficult to distinguish between overdispersion due to unaccounted for 
factors and a time trend by looking solely at contingency tables because of their 
multivariate nature.  A 2x2x2 table for instance has 8 cells.  The (log) odds-ratio is the 
natural metric for measuring association in 2x2 tables. Higher-order associations 
(interactions involving three or more drugs) are quantified by contrasts between log 
odds-ratios in partial 2x2 tables. For example, the most general association model for a 
2x2x2 table is given by: 
log ( ' =` + `a +  `b + `'c + ` ab + `'ac +  `'bc + ` 'abc        (2) 
where , ), and  denote three different drugs, subscripts , , and  indicate the 
susceptible/resistant combination for the three drugs (1=susceptible, 2=resistant), the 
(′T are the expected cell counts and the `′T are model coefficients constrained to be 
zero whenever , , or  equal 1 for identifiability.  In this case the parameter `"""abcis a 
contrast between log odds-ratios in two partial tables, and quantifies the level of 
interaction between the three drugs.  If `"""abc=0, the log odds-ratios for drugs X and Y 
is the same whether drug Z is resistant or susceptible. On the other hand, if ` 'abc=0.5, 
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the X-Y odds-ratio is .=1.65 times higher when Z is resistant than when it is 
susceptible.  
For a univariate statistic we can measure overdispersion by taking the ratio of 
observed variance over the years in the data set to expected variance assuming 
multinomial variation and no time trend, by calculating the test statistic 
∑ W}~<0}~7NOA>∆NONO∆NO∈b&         (3) 
where : is the total number of observations,  the vector of estimated contingency 
table cell frequencies, NO is a function of the cell proportions, ∆ indicates the 
gradient, and Σ is a covariance matrix.  Under the null hypothesis this test statistic has 
a chi-squared distribution with Years-1 degrees of freedom. In the special case in 
which NO is the coefficient for the K-drug association in a 2K table, the expected 
variance assuming multinomial variation and no time trend can be approximated using 
the delta method as 
∑ L~hh~hh∈~hhW         (4) 
where  denotes an estimated cell frequency in the marginal table obtained by 
collapsing over years and n is the total sample size. As with the general Pearson 
statistic, large values relative to this null distribution are an indication of 
overdispersion.  
Asymptotic power analysis 
Under multinomial sampling, the ratio of an estimated coefficient to its 
standard deviation approximately follows a standard normal distribution 
asymptotically in the null case. In the non-null case the distribution of this ratio 
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approximately follows a non-central standard normal distribution with a non-centrality 
parameter given by 
∆	= &NO        (5) 
where ` is the coefficient, and TN`O is the standard error of the estimated coefficient. 
Equivalently, the square of this statistic approximately follows a non-central chi-
squared distribution with non-centrality parameter ∆". 
One of the primary problems with overdispersion is that it decreases the power 
to reject a null hypothesis that is in fact false. This is due to the fact that 
overdispersion inflates the variance of an estimated coefficient by a factor V >1. In 
this case, one might consider adjusting the non-centrality parameter to 
∆	= &NO        (6) 
Power simulation 
 The analysis above assumes the ratio of an estimated coefficient to its standard 
deviation follows a (possibly non-central) standard normal distribution.  This may be 
essentially true when the expected counts in all cells are sufficiently large, but will 
hold less exactly for tables with small cell counts resulting from large interaction 
coefficients, or high levels of overdispersion.  Figure 1 shows qq-plots comparing the 
theoretical normal distribution for a given sample size and log-linear model with that 
resulting from a process similar to the one generating the NARMS data.  Specifically, 
cell frequencies are drawn from a Direchlet distribution with parameters chosen to 
produce expected counts satisfying the given model with a specified level of 
overdispersion and then cell counts are drawn from a multinomial with the just drawn  
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Figure 1: Quantile-quantile plots comparing the theoretical normal distribution for the 
highest order interaction term in a log linear model of a contingency table to a 
Dirichlet-multinomial distribution that more accurately models the process generating 
the underlying contingency table.  The null model in the upper left corner has a total 
count of 1000 and form log ( ' = − 1.836	 − .4055 +	 .04886 − .8598 + .4055 +
.4055 + .4055 which corresponds to a contingency table for three variables with 
resistance probabilities .4, .5, and .6 where all two-way odds ratios are 1.5. 
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cell frequencies and the chosen sample size.  The plots begin with a null model having 
a total count of 1000 and form log ( ' = − 1.836	 − .4055 +	 .04886 − .8598 +
.4055 + .4055 + .4055 which corresponds to a contingency table for three variables 
with resistance probabilities .4, .5, and .6 where all two-way odds ratios are 1.5.  As 
both the interaction coefficient and the amount of overdispersion increase the qq-plots 
leave the unit slope diagonal to a larger degree indicating that the distributions are 
becoming more different.  
 To account for possible inaccuracy of the normal/chisquared approximation, 
we recalculated the power via the Dirichlet-multinomial simulation.  The critical value 
for a test of the null model (at, say, significance level alpha) was determined as the 
empirical (1-alpha)-quantile of the test-statistic. The power to detect the alternatives to 
the null was estimated by the proportion of test-statistics simulated under the 
alternative that exceeded the null critical value.  
Results 
Analysis of multivariate overdispersion 
For each of the 7 years at slaughter, retail and the combined data there are 5 
multiway tables to consider, the four-way table for gentamicin, sulfisoxazole, 
tetracycline and ampicillin and the 4 subsidiary three-way tables.  With the exception 
of 2007 when there was no testing for sulfisoxazole, sample sizes range from 600 to 
2200 a year for slaughter, 300 to 400 at retail, and 300 to 2600 over all (Table 1). At 
slaughter and over all the probabilities of observing as much or more variability than 
seen in the data by chance alone is less than .00001 (Table 2).  The p-values for retail  
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Table 1. Sample sizes by year and production stage. 
Year Slaughter Retail Total 
2004 1695 400 2095 
2005 2232 393 2625 
2006 1357 418 1775 
2007 0 299 299 
2008 986 306 1292 
2009 876 314 1190 
2010 941 357 1298 
2011 613 341 954 
2012 990 386 1376 
 
 
 
 
 
Table 2. P-values for the test of overdispersion in year to year variation of cell counts 
in multiway antimicrobial resistance interaction contingency tables. 
Interaction Slaughter Retail Total 
Gentamicin:Sulfisoxazole:Tetracycline <.000001 .0000691 <.000001 
Gentamicin:Sulfisoxazole: Ampicillin <.000001 0.000611 <.000001 
Gentamicin:Tetracycline:Ampicillin <.000001 .0000223 <.000001 
Sulfisoxazole:Tetracycline:Ampicillin <.000001 .0000307 <.000001 
Gentamicin:Sulfisoxazole:Tetracycline: 
Ampicillin 
<.000001 0.000318 <.000001 
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are slightly higher ranging from .0000975 for Gentamicin:Sulfisoxazole:Tetracycline 
to 0.00166 for the four-way table. 
Overdispersion of the interaction parameters 
 Consistent with the multinomial analysis the interaction parameters also 
exhibit a greater than expected amount of variability (Table 2, Table 3, Table 4).  The 
three-way interaction coefficient among gentamicin, sulfisoxazole, and tetracycline 
has no trend at any stage (Figure 2).  It is generally positive with a mean of 0.859 at 
slaughter, 0.970 at retail, and .883 in the full dataset, but it does have a negative 
estimate in 2008 at retail.  The overdispersion factor for this interaction is 3.05 at 
slaughter, 3.11 at retail and 4.83 in the combined data.  The three-way interaction 
among gentamicin, sulfisoxazole and ampicillin is generally positive with no trend at 
any stage, but 2005 has a negative estimate at all three sages (Figure 3).  The mean 
interaction parameter is 1.03 at slaughter, 2.19 at retail, and 1.34 over all.  The 
overdispersion factors are 3.15 at slaughter, 4.14 at retail and 4.65 in the combined 
data.  The three-factor interaction for gentamicin, tetracycline, and ampicillin has one 
negative estimate in 2004 at retail, otherwise it is positive with no trend (Figure 4).  
The interaction parameter means are .46 at slaughter, .75 at retail, and .53 overall.  The 
overdispersion factors are 2.01 at slaughter, 3.04 at retail, and 2.65 combined.  The 
three factor sulfisoxazole, tetracycline, ampicillin interaction is fairly close to 0 with 
no trend over time (Figure 5).  Its mean is .32 at slaughter, .16 at retail, and .30 
overall.  The overdispersion factors are 3.00 at slaughter, 1.93 at retail, and 2.43 
overall.  The four-factor interaction among gentamicin, sulfisoxazole, tetracycline, and 
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ampicillin has an increasing trend from -2.5 to 2.5 at slaughter and overall (Figure 6), 
but it must 
 
Table 3. Overdispersion factor for the highest order interaction parameter in the log-
liner model of the multidrug contingency table. 
Interaction Slaughter Retail Total 
Gentamicin:Sulfisoxazole:Tetracycline: 3.05 3.11 4.83 
Gentamicin:Sulfisoxazole:Ampicillin 3.15 4.14 4.65 
Gentamicin:Tetracycline:Ampicillin 2.01 3.04 2.65 
Sulfisoxazole:Tetracycline:Ampicillin 3.00 1.93 2.43 
Gentamicin:Sulfisoxazole:Tetracycline: 
Ampicillin 
5.87 3.09 5.77 
 
 
 
Table 4. Overdispersion test p-values for the highest order interaction parameter in the 
log-liner model of the multidrug contingency table. 
Interaction Slaughter Retail Total 
Gentamicin:Sulfisoxazole:Tetracycline <.000001 <.000001 <.000001 
Gentamicin:Sulfisoxazole: Ampicillin <.000001 <.000001 <.000001 
Gentamicin:Tetracycline:Ampicillin <.000001 <.000001 <.000001 
Sulfisoxazole:Tetracycline:Ampicillin <.000001 <.000001 <.000001 
Gentamicin:Sulfisoxazole:Tetracycline: 
Ampicillin 
<.000001 <.000001 <.000001 
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Figure 2: Plot of the highest order interaction parameter in the log-liner model of the 
gentamicin, sulfisoxazole, and tetracycline multidrug contingency table by year and 
stage. 
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Figure 3: Plot of the highest order interaction parameter in the log-liner model of the 
gentamicin, sulfisoxazole, and ampicillin multidrug contingency table by year and 
stage. 
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Figure 4: Plot of the highest order interaction parameter in the log-liner model of the 
gentamicin, tetracycline, and ampicillin multidrug contingency table by year and 
stage. 
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Figure 5: Plot of the highest order interaction parameter in the log-liner model of the 
sulfisoxazole, tetracycline, and ampicillin multidrug contingency table by year and 
stage.
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Figure 6: Plot of the highest order interaction parameter in the log-liner model of the 
gentamicin, sulfisoxazole, tetracycline, and ampicillin multidrug contingency table by 
year and stage. 
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be kept in mind that such a trend could just be the product of overdispersion.  At retail 
it has a mean of 1.60 with no trend and an over dispersion factor of 3.09. 
Power analysis 
 In our data interaction parameters ranged in magnitude from 0 to 4, 
overdispersion parameters ranged from 2 to 6 and sample sized ranged from 300 to 
10,000 depending on how many years were pooled.  We consider .8 to be a minimum 
desirable power. 
For the null model with form log ( ' = − 1.836	 − .4055 +	 .04886 −
.8598 + .4055 + .4055 + .4055 and an overdispersion of 3 a sample size of 2,500 
would be required to detect an interaction parameter of 1 and a sample of 500 would 
be required to detect an interaction parameter of 2 (Figure 7).  For sample sizes of 100 
and 500 the powers determined from the simulation are slightly lower than theoretical 
values based on the normal assumption.  For a sample of 100 the theoretical power is 
about .01 lower than the theoretical value at an interaction parameter of 2. 
When the interaction parameter is fixed and the overdispersion is instead 
allowed to vary a sample size of 1000 would be sufficient to detect an interaction 
parameter of 1 at an overdispersion of 1.75, and a sample size of 2,500 could detect 
such an interaction at an overdispersion of 4.5 (Figure 8).  Interestingly, at an 
interaction parameter of 1 there is little difference between the powers calculated from 
the simulated and theoretical distributions.  For detecting an interaction parameter of 2 
a sample size of 500 would be sufficient up to an overdispersion of 3 and a sample  
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Figure 7: Power curves for detecting the highest order interaction in a log-linear model 
of a contingency table under various settings of the interaction parameter and sample 
size at a fixed overdispersion of 3 when the null model has form log ( ' = −
1.836	 − .4055 +	 .04886 − .8598 + .4055 + .4055 + .4055.  Solid lines are 
calculated using the assumption of asymptotic normality, and dashed lines are 
calculated using simulations from a Dirichlet-multinomial distribution.   
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Figure 8: Power curves for detecting the highest order interaction in a log-linear model 
of a contingency table under various settings of the overdispersion and sample size at 
a fixed interaction parameter of 1 when the null model has form log ( ' = − 1.836	 −
.4055 +	 .04886 − .8598 + .4055 + .4055 + .4055.  Solid lines are calculated using 
the assumption of asymptotic normality, and dashed lines are calculated using 
simulations from a Dirichlet-multinomial distribution.  
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Figure 9: Power curves for detecting the highest order interaction in a log-linear model 
of a contingency table under various settings of the overdispersion and sample size at 
a fixed interaction parameter of 2 when the null model has form log ( ' = − 1.836	 −
.4055 +	 .04886 − .8598 + .4055 + .4055 + .4055.  Solid lines are calculated using 
the assumption of asymptotic normality, and dashed lines are calculated using 
simulations from a Dirichlet-multinomial distribution. 
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size of 1000 would be sufficient up to an overdispersion of 6 (Figure 9).  At this level 
of the interaction parameter there begins to be a discrepancy between theoretical and 
simulated powers.  At a sample size of 100, the power calculated from the theoretical 
distribution is almost .025 higher than that calculated through simulation. 
Conclusion 
 Year on year contingency table analysis of multidrug resistance to gentamicin, 
sulfisoxazole, tetracycline and ampicillin by E. coli isolated from chicken at slaughter 
and retail in the years 2004 to 2012 by NARMS suggests overdispersion with respect 
to multinomial variation. The overdispersion is apparent both at the multivariate 
(whole table) level, and on the level of individual interactions.  In some cases, like the 
interaction among gentamicin, sulfisoxazole, and tetracycline at retail, this 
overdispersion comes from hyper-variability around a consistent mean even 
sometimes switching signs in different years.  In other cases, like the interaction 
among gentamicin, sulfisoxazole, tetracycline, and ampicillin at slaughter and overall, 
there seems to be an increasing trend in the interaction parameter, although this may 
simply be the result of overdispersion. 
 This overdispersion is problematic for surveillance systems like NARMS 
because it increases the sample sizes needed to detect interactions.  In fact, the sample 
sizes needed to achieve a power greater than .8 for detecting a highest order 
interaction parameter of 1 at an overdispersion of 3 exceed 2,500 and thus, at current 
rates of NARMS data collection would take several years to achieve.  This power can 
be accurately approximated with the asymptotic normal assumption at high sample 
sizes, low overdispersions and small interaction parameters.  The approximation is not 
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strictly valid, however, for low sample sizes, high overdispersions and large 
interaction parameters where an improved power estimate can be obtained using a 
Dirichlet-multinomial simulation approach. 
Much of the overdispersion observed in this study is likely do to uncontrolled 
latent variables, like antimicrobial use, husbandry and hygiene practices.  Interestingly 
though, the slaughter data which has a less consistent sampling design than the retail 
program in some cases had lower levels of overdispersion.  This indicates that while 
more careful sampling design could help to improve power in surveillance systems 
like NARMS, much of the variability is likely to be endemic to the enterprise of 
antimicrobial resistance surveillance. 
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CHAPTER 5 
CONCLUSION  
Summary 
Surveillance is a key component of controlling antimicrobial resistance.  In the 
United States this surveillance is carried out by the National Antimicrobial Resistance 
Monitoring System (NARMS).  In this system, the United States Department of 
Agriculture Food Safety Inspection Service collects isolates from slaughter facilities, 
the Food and Drug Administration collects Isolates from Grocery Stores, and the 
Center for Disease Control and Prevention collect isolates from human medicine.   
Examination of resistance to single drugs reveals that resistance patterns 
depend very much on the antibiotic, microbe, host and stage under consideration.  
Resistance of Eschereschia coli isolated from chicken to streptomycin has decreased 
steadily over time at both slaughter and retail.  By contrast resistance of Salmonella 
Typhimurium isolated from chickens to ampicillin has increased slightly at retail, but 
decreased at slaughter.  This dependence on context occurs both when then magnitude 
of resistance is measured as a minimum inhibitory concentration and for binary 
resistance/susceptibility determined using a threshold.  What does change, is the trend 
in resistance.  This may at first seem problematic, but makes sense when we consider 
that modifying the choice of resistance cutoff effectively askes a different question 
about resistance, a new question with a new answer.  Another consistent aspect of the 
data is higher than expected variability.  The standard deviation for counts of resistant 
isolates exceeds expected binomial standard deviation and the amount by which it 
exceeds the expected value is independent of samples size.  The variation in MICs is 
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greater within a given year than between years.  This greater than expected variability 
makes it difficult to detect changes in resistance.  In particular, it would take up to 6 
years of data collection at the current rate to detect even a 6% change in resistance. 
As serious a threat as single drug resistance poses to our ability to control 
infections multidrug resistance compounds this effect.  Fortunately, the NARMS data 
provides a trove of information about this problem.  By constructing contingency 
tables of resistance counts and modeling them with log-linear models we can detect 
not just pairwise associations but also higher order interactions among antibiotic 
resistances.  A prime example of this is the four-way interaction among the β-lactams 
amoxicillin-clavulanic acid, ceftriaxone, cefoxitin and ceftiofur.  Many of these 
interactions, such as this four way β-lactam interaction have such extreme odds ratios 
they cannot be tested for using asymptotic or exact conditional methods, but instead 
require a Bayesian approach.  Inference of these interactions sheds important light on 
the structure of multidrug resistance.  This structure can help inform clinical practices 
on which antibiotics to prescribe.  They also can shed light into the mechanisms by 
which resistance develops as in the case of the hierarchal ordering of β-lactam 
resistance that creates its extreme four-way interaction. 
Examination of the multidrug interactions over time shows they exhibit greater 
than expected variability.  This is not surprising given that there is over dispersion in 
the single drug resistances.  The overdispersion makes it more difficult to detect these 
associations as it would take a sample size of 2,500 to detect an interaction parameter 
of 1 at the levels of overdispersion observed in the NARMS data. 
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The overdispersion observed in both the single drug and multidrug data make 
it difficult to estimate with high precision quantities of interest such as interaction 
parameters or changes in resistance.  The existence of this overdispersion indicates the 
existence of unmeasured covariates.   The list of potential covariates is extensive, 
including antimicrobial use, climate, animal husbandry practices, hygiene practices, 
and available carbon sources. In fact, because antimicrobial resistance is a product of 
natural selection any factor that effects the fitness of microbes carrying resistance 
traits is a relevant covariate.  The observation that most variability in single drug 
resistance is within year not between years and that the more consistent sampling 
design of the retail program than the slaughter program did not uniformly decrease 
overdispersion suggests that there are unlikely to be any silver bullet covariates that by 
themselves produce a dramatic decrease in overdispersion.  Undoubtedly increasing 
the number of measured covariates would help decrease overdispersion in the 
NARMS data.  There are a number of variables, like measuring the state in which 
slaughter samples were collected, that could be collected at little to no extra cost, and 
are ripe for the picking.  Nonetheless overdispersion is likely to be a fundamental part 
of antimicrobial resistance surveillance, especially in a country as large as the United 
States. 
Future Directions 
 All the work up to this point has been phenotypic, focusing simply on 
resistance with no data on the underlying genotypes.  Arguably the most important 
addition that could be made to the current work is adding in this genotypic 
information.  On the single drug level whole genome sequence data would allow us to 
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identify which genes are most important in leading to the increases in resistance.  It 
would help in determining if changes in resistance in different regions are the result of 
the same strains or different strains.  On the multi-drug level whole genome 
sequencing would provide an important actionable way of following up on the 
potential mechanisms identified in the log linear models.
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